In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program
Abstract The 2013 LEADER surveillance program monitored the in vitro activity of linezolid and comparator agents against Gram-positive bacteria at 60 medical centers in the United States. A total of 7183 pathogens were contributed from 6 predetermined pathogen groups. The groups were Staphylococcus...
Gespeichert in:
| Veröffentlicht in: | Diagnostic microbiology and infectious disease 2015-04, Vol.81 (4), p.283-289 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 289 |
|---|---|
| container_issue | 4 |
| container_start_page | 283 |
| container_title | Diagnostic microbiology and infectious disease |
| container_volume | 81 |
| creator | Flamm, Robert K Mendes, Rodrigo E Hogan, Patricia A Ross, James E Farrell, David J Jones, Ronald N |
| description | Abstract The 2013 LEADER surveillance program monitored the in vitro activity of linezolid and comparator agents against Gram-positive bacteria at 60 medical centers in the United States. A total of 7183 pathogens were contributed from 6 predetermined pathogen groups. The groups were Staphylococcus aureus , coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae , β-hemolytic streptococci, and viridans group streptococci. The MIC90 value for each of the 6 pathogen groups was 1 μg/mL. Susceptibility of “all organisms” to linezolid was 99.83%. Only 12 isolates (2 S. aureus , 3 Staphylococcus epidermidis , 1 Streptococcus sanguinis , 5 Enterococcus faecium , and 1 Enterococcus faecalis ) were nonsusceptible to linezolid (0.17%). Three of these (2 S. aureus and 1 E. faecium ) harbored the cfr resistance mechanism. The findings indicate that linezolid activity remains stable, although there are examples of clonal dissemination within several monitored institutions. |
| doi_str_mv | 10.1016/j.diagmicrobio.2014.12.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1665494774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0732889314005197</els_id><sourcerecordid>1665494774</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-ffc5fe75d9b68d731a9deffffa149b067f41fbf1b8750bcdd918ecd4f98fd8103</originalsourceid><addsrcrecordid>eNqNkU9v1DAQxS0EokvhKyCLE5eEceLEMQekql3aSish8UccLcceb70k62InKy2fvo62IMQJa6Tx4c08-_cIecOgZMDad7vSer0dvYmh96GsgPGSVSWAfEJWrBOyABDwlKxA1FXRdbI-Iy9S2gGwSnJ4Ts6qpq1rXsGKfL_d04OfYqDaTD7fjjQ4Ovg9_gqDt1SnXAlzWTrdxTBv73JHmk1rullfXK0_0zTHA_ph0HuD9D6GbdTjS_LM6SHhq8d-Tr59XH-9vCk2n65vLy82hWmgmQrnTONQNFb2bWdFzbS06PLRjMseWuE4c71jfSca6I21knVoLHeyc7ZjUJ-Tt6e92ffnjGlSo08Gl8dgmJNibdtwyYXgWfr-JM3cUoro1H30o45HxUAtYNVO_Q1WLWAVq1QGm4dfP_rM_Yj2z-hvkllwdRJg_u3BY1TJeMxErI9oJmWD_z-fD_-sMTkMb_TwA4-YdmGO-8xTMZXygPqyRLwkzDhAw6SoHwDO8aZG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1665494774</pqid></control><display><type>article</type><title>In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Flamm, Robert K ; Mendes, Rodrigo E ; Hogan, Patricia A ; Ross, James E ; Farrell, David J ; Jones, Ronald N</creator><creatorcontrib>Flamm, Robert K ; Mendes, Rodrigo E ; Hogan, Patricia A ; Ross, James E ; Farrell, David J ; Jones, Ronald N</creatorcontrib><description>Abstract The 2013 LEADER surveillance program monitored the in vitro activity of linezolid and comparator agents against Gram-positive bacteria at 60 medical centers in the United States. A total of 7183 pathogens were contributed from 6 predetermined pathogen groups. The groups were Staphylococcus aureus , coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae , β-hemolytic streptococci, and viridans group streptococci. The MIC90 value for each of the 6 pathogen groups was 1 μg/mL. Susceptibility of “all organisms” to linezolid was 99.83%. Only 12 isolates (2 S. aureus , 3 Staphylococcus epidermidis , 1 Streptococcus sanguinis , 5 Enterococcus faecium , and 1 Enterococcus faecalis ) were nonsusceptible to linezolid (0.17%). Three of these (2 S. aureus and 1 E. faecium ) harbored the cfr resistance mechanism. The findings indicate that linezolid activity remains stable, although there are examples of clonal dissemination within several monitored institutions.</description><identifier>ISSN: 0732-8893</identifier><identifier>EISSN: 1879-0070</identifier><identifier>DOI: 10.1016/j.diagmicrobio.2014.12.009</identifier><identifier>PMID: 25633420</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Academic Medical Centers ; Adult ; Anti-Bacterial Agents - pharmacology ; Drug Resistance, Bacterial ; Enterococcus - drug effects ; Enterococcus - isolation & purification ; Female ; Gram-Positive Bacterial Infections - microbiology ; Humans ; Infectious Disease ; Internal Medicine ; LEADER ; Linezolid ; Linezolid - pharmacology ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Oxazolidinones ; Staphylococcus - drug effects ; Staphylococcus - isolation & purification ; Streptococcus - drug effects ; Streptococcus - isolation & purification ; United States ; Young Adult</subject><ispartof>Diagnostic microbiology and infectious disease, 2015-04, Vol.81 (4), p.283-289</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-ffc5fe75d9b68d731a9deffffa149b067f41fbf1b8750bcdd918ecd4f98fd8103</citedby><cites>FETCH-LOGICAL-c505t-ffc5fe75d9b68d731a9deffffa149b067f41fbf1b8750bcdd918ecd4f98fd8103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.diagmicrobio.2014.12.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25633420$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Flamm, Robert K</creatorcontrib><creatorcontrib>Mendes, Rodrigo E</creatorcontrib><creatorcontrib>Hogan, Patricia A</creatorcontrib><creatorcontrib>Ross, James E</creatorcontrib><creatorcontrib>Farrell, David J</creatorcontrib><creatorcontrib>Jones, Ronald N</creatorcontrib><title>In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program</title><title>Diagnostic microbiology and infectious disease</title><addtitle>Diagn Microbiol Infect Dis</addtitle><description>Abstract The 2013 LEADER surveillance program monitored the in vitro activity of linezolid and comparator agents against Gram-positive bacteria at 60 medical centers in the United States. A total of 7183 pathogens were contributed from 6 predetermined pathogen groups. The groups were Staphylococcus aureus , coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae , β-hemolytic streptococci, and viridans group streptococci. The MIC90 value for each of the 6 pathogen groups was 1 μg/mL. Susceptibility of “all organisms” to linezolid was 99.83%. Only 12 isolates (2 S. aureus , 3 Staphylococcus epidermidis , 1 Streptococcus sanguinis , 5 Enterococcus faecium , and 1 Enterococcus faecalis ) were nonsusceptible to linezolid (0.17%). Three of these (2 S. aureus and 1 E. faecium ) harbored the cfr resistance mechanism. The findings indicate that linezolid activity remains stable, although there are examples of clonal dissemination within several monitored institutions.</description><subject>Academic Medical Centers</subject><subject>Adult</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Drug Resistance, Bacterial</subject><subject>Enterococcus - drug effects</subject><subject>Enterococcus - isolation & purification</subject><subject>Female</subject><subject>Gram-Positive Bacterial Infections - microbiology</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>Internal Medicine</subject><subject>LEADER</subject><subject>Linezolid</subject><subject>Linezolid - pharmacology</subject><subject>Male</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Oxazolidinones</subject><subject>Staphylococcus - drug effects</subject><subject>Staphylococcus - isolation & purification</subject><subject>Streptococcus - drug effects</subject><subject>Streptococcus - isolation & purification</subject><subject>United States</subject><subject>Young Adult</subject><issn>0732-8893</issn><issn>1879-0070</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU9v1DAQxS0EokvhKyCLE5eEceLEMQekql3aSish8UccLcceb70k62InKy2fvo62IMQJa6Tx4c08-_cIecOgZMDad7vSer0dvYmh96GsgPGSVSWAfEJWrBOyABDwlKxA1FXRdbI-Iy9S2gGwSnJ4Ts6qpq1rXsGKfL_d04OfYqDaTD7fjjQ4Ovg9_gqDt1SnXAlzWTrdxTBv73JHmk1rullfXK0_0zTHA_ph0HuD9D6GbdTjS_LM6SHhq8d-Tr59XH-9vCk2n65vLy82hWmgmQrnTONQNFb2bWdFzbS06PLRjMseWuE4c71jfSca6I21knVoLHeyc7ZjUJ-Tt6e92ffnjGlSo08Gl8dgmJNibdtwyYXgWfr-JM3cUoro1H30o45HxUAtYNVO_Q1WLWAVq1QGm4dfP_rM_Yj2z-hvkllwdRJg_u3BY1TJeMxErI9oJmWD_z-fD_-sMTkMb_TwA4-YdmGO-8xTMZXygPqyRLwkzDhAw6SoHwDO8aZG</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Flamm, Robert K</creator><creator>Mendes, Rodrigo E</creator><creator>Hogan, Patricia A</creator><creator>Ross, James E</creator><creator>Farrell, David J</creator><creator>Jones, Ronald N</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program</title><author>Flamm, Robert K ; Mendes, Rodrigo E ; Hogan, Patricia A ; Ross, James E ; Farrell, David J ; Jones, Ronald N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-ffc5fe75d9b68d731a9deffffa149b067f41fbf1b8750bcdd918ecd4f98fd8103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Academic Medical Centers</topic><topic>Adult</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Drug Resistance, Bacterial</topic><topic>Enterococcus - drug effects</topic><topic>Enterococcus - isolation & purification</topic><topic>Female</topic><topic>Gram-Positive Bacterial Infections - microbiology</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>Internal Medicine</topic><topic>LEADER</topic><topic>Linezolid</topic><topic>Linezolid - pharmacology</topic><topic>Male</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Oxazolidinones</topic><topic>Staphylococcus - drug effects</topic><topic>Staphylococcus - isolation & purification</topic><topic>Streptococcus - drug effects</topic><topic>Streptococcus - isolation & purification</topic><topic>United States</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Flamm, Robert K</creatorcontrib><creatorcontrib>Mendes, Rodrigo E</creatorcontrib><creatorcontrib>Hogan, Patricia A</creatorcontrib><creatorcontrib>Ross, James E</creatorcontrib><creatorcontrib>Farrell, David J</creatorcontrib><creatorcontrib>Jones, Ronald N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diagnostic microbiology and infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Flamm, Robert K</au><au>Mendes, Rodrigo E</au><au>Hogan, Patricia A</au><au>Ross, James E</au><au>Farrell, David J</au><au>Jones, Ronald N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program</atitle><jtitle>Diagnostic microbiology and infectious disease</jtitle><addtitle>Diagn Microbiol Infect Dis</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>81</volume><issue>4</issue><spage>283</spage><epage>289</epage><pages>283-289</pages><issn>0732-8893</issn><eissn>1879-0070</eissn><abstract>Abstract The 2013 LEADER surveillance program monitored the in vitro activity of linezolid and comparator agents against Gram-positive bacteria at 60 medical centers in the United States. A total of 7183 pathogens were contributed from 6 predetermined pathogen groups. The groups were Staphylococcus aureus , coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae , β-hemolytic streptococci, and viridans group streptococci. The MIC90 value for each of the 6 pathogen groups was 1 μg/mL. Susceptibility of “all organisms” to linezolid was 99.83%. Only 12 isolates (2 S. aureus , 3 Staphylococcus epidermidis , 1 Streptococcus sanguinis , 5 Enterococcus faecium , and 1 Enterococcus faecalis ) were nonsusceptible to linezolid (0.17%). Three of these (2 S. aureus and 1 E. faecium ) harbored the cfr resistance mechanism. The findings indicate that linezolid activity remains stable, although there are examples of clonal dissemination within several monitored institutions.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25633420</pmid><doi>10.1016/j.diagmicrobio.2014.12.009</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-8893 |
| ispartof | Diagnostic microbiology and infectious disease, 2015-04, Vol.81 (4), p.283-289 |
| issn | 0732-8893 1879-0070 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1665494774 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Academic Medical Centers Adult Anti-Bacterial Agents - pharmacology Drug Resistance, Bacterial Enterococcus - drug effects Enterococcus - isolation & purification Female Gram-Positive Bacterial Infections - microbiology Humans Infectious Disease Internal Medicine LEADER Linezolid Linezolid - pharmacology Male Microbial Sensitivity Tests Middle Aged Oxazolidinones Staphylococcus - drug effects Staphylococcus - isolation & purification Streptococcus - drug effects Streptococcus - isolation & purification United States Young Adult |
| title | In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T02%3A55%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20activity%20of%20linezolid%20as%20assessed%20through%20the%202013%20LEADER%20surveillance%20program&rft.jtitle=Diagnostic%20microbiology%20and%20infectious%20disease&rft.au=Flamm,%20Robert%20K&rft.date=2015-04-01&rft.volume=81&rft.issue=4&rft.spage=283&rft.epage=289&rft.pages=283-289&rft.issn=0732-8893&rft.eissn=1879-0070&rft_id=info:doi/10.1016/j.diagmicrobio.2014.12.009&rft_dat=%3Cproquest_cross%3E1665494774%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1665494774&rft_id=info:pmid/25633420&rft_els_id=S0732889314005197&rfr_iscdi=true |